Progressive Familial Intrahepatic Cholestasis Type 2 and Recurrence After Liver Transplantation: A Case Report

Silas Gustavo Barboza Romeres,Natália de Carvalho Trevizoli,Carolina Augusta Matos de Oliveira,Evelyn Jacome Obeid,Gustavo de Sousa Arantes Ferreira,Priscila Brizolla De Campos,Raquel Francine Bundchen Ullmann,Henrique Carvalho Rocha,Ana Virgínia Ferreira Figueira,Luiz Gustavo Guedes Diaz,Fernando Marcus Felippe Jorge,Gabriel Oliveira Nunes Caja,André Luis Conde Watanabe,Evandro Sobroza de Mello,Elisa de Carvalho

DOI: https://doi.org/10.1016/j.transproceed.2022.04.007

Abstract:Progressive familial intrahepatic cholestasis type 2 (PFIC2) is a rare autosomal recessive disorder caused by mutations in the ABCB11 gene. Clinical manifestations include cholestasis with low γ-glutamyltransferase (GGT), hepatosplenomegaly, and severe pruritus. Liver transplantation is required for individuals with progressive liver disease or failure of the bypass procedure and has been considered curative. However, in the case of PFIC2, although bile salt excretory pump (BSEP) deficiency is a liver-specific condition rather than a systemic disease, evidence of recurrent BSEP disease has been shown in a small proportion of allografts. We describe an unusual case of a 21-year-old individual with PFIC2 and evidence of recurrent BSEP disease after liver transplantation, with clinical and laboratory improvement after pulse therapy with methylprednisolone for 3 days and adjustment of oral immunosuppression. This case report highlights the recurrence of PFIC2 in patients post liver transplant. It also emphasizes the importance of clinical suspicion, which should be considered in cases of posttransplant cholestasis in PFIC2 patients, especially those with low γ-glutamyltransferase (GGT) and without signs of acute graft rejection. Having knowledge of the condition favors a targeted diagnostic approach and contributes to early therapeutic management and a higher success rate.